MedTrace Logo

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.

The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Conditions

Interventions

DRUG

VTX958 Dose A

Dose A

DRUG

VTX958 Dose B

Dose B

DRUG

VTX958 Dose C

Dose C

DRUG

VTX958 Dose D

Dose D

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Ventyx Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Snehal Naik, PhD · Ventyx Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-17
Primary Completion
2023-09-25
Completion
2023-12-20
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05655299 on ClinicalTrials.gov